ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026
Rhea-AI Summary
ZEO ScientifiX (OTCQB:ZEOX) reported sharp revenue growth for the quarter and six months ended April 30, 2026. Quarterly revenue rose 124.6% to $2.58 million, while six-month revenue increased 79.9% to $4.03 million, mainly from allogenic biologic products.
The company maintained approximately 80% gross margins for the six-month periods in 2026 and 2025 and reduced its six-month net loss to about $1.0 million from $2.6 million a year earlier, reflecting expanding demand, higher physician adoption, and broader awareness of its regenerative biologics portfolio.
Positive
- Quarterly revenue up 124.6% to $2,581,000 year-over-year
- Six-month revenue up 79.9% to $4,027,000 year-over-year
- Approximately 80% gross margins maintained over both six-month periods
- Six-month net loss reduced to about $1.0 million from $2.6 million
- Growth driven by increased demand for allogenic and stem-cell-focused biologic products
Negative
- Company remains unprofitable with a six-month net loss of about $1.0 million
News Market Reaction – ZEOX
In the Jul 8 session, ZEOX gained 1.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company reports revenue growth of
DAVIE, FL / ACCESS Newswire / July 8, 2026 / ZEO ScientifiX, Inc. (OTCQB:ZEOX) ("ZEO ScientifiX" or the "Company"), a biologics research and products company advancing regenerative medicine, physician education, and next-generation biologic technologies, today announced that it had reported exceptional year-over-year revenue growth, stronger gross margins, and improved operating performance in its recently filed Form 10-Q for the Quarter ended April 30, 2026 (the "Form 10-Q").
In the Form 10-Q, the Company provided the following information:
"Revenues. Our revenues for the three months ended April 30, 2026 were
Revenues. Our revenues for the six months ended April 30, 2026 were
The Company's three and six month performance reflects significant commercial acceleration across its regenerative biologics portfolio, driven by increased demand for stem-cell-focused biologic products in the state of Florida, continued growth in allogenic product sales, expanded physician adoption of its therapeutics, and broader awareness of ZEO's biologic technologies through physician education, conferences, and other commercial initiatives.
ZEO ScientifiX maintained gross margins of approximately
"Our results for the recently reported six months ended April 30, 2026 marks an important inflection point for ZEO ScientifiX," said Ian Bothwell, Chief Executive Officer of ZEO ScientifiX. "We are seeing meaningful growth momentum across the business as more physicians look to ZEO as a trusted supplier and educational partner for their regenerative medicine. Our team has worked relentlessly on safety, research and quality, all helping to expand awareness, strengthen relationships, and support the safe and responsible adoption of stem-cell-focused and allogenic biologic technologies. We expect the foundation we are building today will provide ZEO with continued opportunities to expand."
For additional information, complete financial results, and investor resources, please visit ZEO ScientifiX's Investor Relations page and review the Form 10-Q as filed with the U.S. Securities and Exchange Commission.
About ZEO ScientifiX (OTCQB:ZEOX)
ZEO ScientifiX, Inc. (OTCQB:ZEOX) is an SEC-reporting, clinical-stage biopharmaceutical company focused on the research, development, and manufacturing of regenerative biologics. Operating out of Nova Southeastern University's Center of Collaborative Research, the Company translates emerging science into scalable clinical solutions. ZEO ScientifiX supplies clinicians seeking to drive clinical excellence and sustainable practice growth through its cutting-edge biologics and regenerative therapies. For more information, visit https://zeoscientifix.com.
Forward-Looking Statements
Certain statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Actual results could vary dramatically. ZEO has no intention and specifically disclaims any duty to update the information in this press release.
Media Contact
ZEO ScientifiX, Inc.
Ivana Vega
Public Relations
ivega@zeoscientifix.com
SOURCE: Zeo ScientifiX, Inc.
View the original press release on ACCESS Newswire